Table 2.
Summary of patient characteristics
| Patient characteristics | Number of studies (n = 299)a, b | Percentage of studies |
|---|---|---|
| Number of patients | 58,412 | |
| Mean (median sample size) | 197 (105)c | |
| Mean % female | 53.1d | |
| Age category | ||
| Adults and elderly (aged ≥18 years) | 192 | 64.21 |
| Adults only (aged ≥18 to ≤65 years) | 56 | 18.73 |
| Children only (aged <18 years) | 25 | 8.36 |
| All ages | 10 | 3.34 |
| Children and adults (aged ≤65 years) | 8 | 2.68 |
| Not reported | 8 | 2.68 |
| Cancer typee | ||
| Lung and respiratory | 144 | 48.16 |
| Breast | 110 | 36.79 |
| Gynecological | 98 | 32.78 |
| Hematological | 91 | 30.43 |
| Unspecified or unknown | 87 | 29.10 |
| Head and neck | 87 | 29.10 |
| Gastrointestinal | 86 | 28.76 |
| Genitourinary | 81 | 27.09 |
| Sarcoma | 47 | 15.72 |
| Not reported | 43 | 14.38 |
| Nervous system | 13 | 4.35 |
| Skin | 11 | 3.68 |
| Optic | 5 | 1.67 |
| Germ cell | 5 | 1.67 |
| Other | 3 | 1.00 |
| Adenocarcinoma | 2 | 0.67 |
| Musculoskeletal | 1 | 0.33 |
| Chemotherapy details | ||
| Cisplatin administeredf | 177 | 59.20 |
| Cisplatin dose ≥ 50 mg/m2 | 116 | 38.80 |
| Concomitant radiotherapy | 12 | 4.01 |
| Adjuvant | 14 | 4.68 |
| Neoadjuvant | 4 | 1.34 |
| Patient background details | ||
| History of motion sickness | 19 | 6.35 |
| History of CINV | 29 | 9.70 |
CINV chemotherapy induced nausea and vomiting
aIncludes unpublished data from conference abstracts and trial protocols (Adel et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carrec et al. 2007, Kadota et al. 2007, Piyush 2011)
bExcept where indicated otherwise
cOne study did not report sample size (n = 1)
dEighteen studies did not report female population size (n = 18)
eThe majority of studies included patients with different diagnoses
fIncludes the 116 studies with a cisplatin dose ≥ 50 mg/m2